Diabetes

Adults with diabetes who used a GLP-1 receptor agonist and underwent surgery requiring general anesthesia had similar odds for postsurgical complications as those receiving other oral diabetes medications, according to study data.

WASHINGTON — An algorithm that uses electronic health record parameters identified glycemic evidence of new-onset diabetes in real time, which could lead to earlier detection of pancreatic ductal adenocarcinoma, according to researchers.

SAN FRANCISCO — An updated evidence-based guideline for the assessment and management of polycystic ovary syndrome includes new recommendations for a timelier diagnosis and evidence that firmly supports PCOS is a risk factor for CVD.

Patients with both diabetes and CAD appeared at significantly greater risk for dementia, especially vascular dementia, according to study findings published in European Journal of Preventive Cardiology.

Individuals prescribed the antidiabetes treatment metformin less likely developed a myeloproliferative neoplasm —potentially also reducing a person’s chances for developing certain cancers — according to data published in Blood Advances.

In patients with type 2 diabetes who underwent ablation for atrial fibrillation, those taking a GLP-1 receptor agonist had lower risk for AF recurrence, mortality and other outcomes, researchers reported at Heart Rhythm 2024.

NEW ORLEANS — A consensus statement on managing diabetic ketoacidosis and hyperosmolar hyperglycemic state for adults with diabetes focuses on preventing recurrence and providing people with the tools to maintain glycemic control.

A noninvasive sensor may measure glucose values by using dielectric spectroscopy to scan radiofrequencies, according to a speaker at the American Association of Clinical Endocrinology Annual Meeting.

Moderate to vigorous aerobic and resistance exercise may improve vascular function among cancer survivors, according to findings presented at American Association for Cancer Research Annual Meeting.

In patients with the obesity phenotype of HF with preserved ejection, semaglutide 2.4 mg improved HF-related symptoms and physical limitations vs. placebo regardless of diuretic use, according to new data from the STEP-HFpEF trials.